Queen Mary University of London-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Queen Mary University of London - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013356
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Queen Mary University of London (Queen Mary), formerly Queen Mary and Westfield College, a subsidiary of University of London, is a research university that offers undergraduate and postgraduate education; and research programs. The university provides graduation and education services in areas of astrophysics, biological and chemical sciences, business and management, comparative literature, computer science, drama, economics and finance; electronic engineering, english, film studies, law, linguistics, materials, mathematical sciences and others. It also provides national research assessments and research funding programs. The university provides education services to students in the UK and abroad. Queen Mary is headquartered in London, the UK.

Queen Mary University of London – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Queen Mary University of London, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Queen Mary University of London, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Queen Mary University of London, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Queen Mary University of London, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Queen Mary University of London, Medical Devices Deals, 2011 to YTD 2017 9
Queen Mary University of London, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Queen Mary University of London, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Queen Mary University of London Enters into Research Agreement with Takeda Pharma 11
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 12
BioInvent And Cancer Research Technology Enter Into Co-Development Agreement With Queen Mary, University of London 14
MRC Technology Enters Into Drug Discovery Agreement With Queen Mary University 15
Licensing Agreements 16
BioMoti Enters into Licensing Agreement with Queen Mary University of London 16
MultiVir Enters into Licensing Agreement with Queen Mary University of London 17
Acquisition 18
Retroscreen Virology Acquires Activiomics for USD6.7 Million 18
Queen Mary University of London – Key Competitors 20
Queen Mary University of London – Key Employees 21
Queen Mary University of London – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Government and Public Interest 23
Jul 14, 2017: Queen Mary University of London: Awarded £8.6m for global health research 23
Feb 07, 2017: NattoPharma Named Partner For Horizon 2020 EU Research Grant 24
Dec 12, 2016: White blood cell treatment could prevent leading cause of fetal death 25
Sep 14, 2016: Barts Health NHS Trust: £6.5m grant to launch new heart disease Biomedical Research Centre 26
May 24, 2016: Vitamin A may help improve pancreatic cancer chemotherapy 28
Mar 28, 2016: Structure of Parkinson’s protein could lead to new diagnostic and treatment options 29
Feb 11, 2016: Common antimalarial drug could be used to treat major injury 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Queen Mary University of London, Pharmaceuticals & Healthcare, Key Facts 2
Queen Mary University of London, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Queen Mary University of London, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Queen Mary University of London, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Queen Mary University of London, Deals By Therapy Area, 2011 to YTD 2017 8
Queen Mary University of London, Medical Devices Deals, 2011 to YTD 2017 9
Queen Mary University of London, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Queen Mary University of London Enters into Research Agreement with Takeda Pharma 11
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 12
BioInvent And Cancer Research Technology Enter Into Co-Development Agreement With Queen Mary, University of London 14
MRC Technology Enters Into Drug Discovery Agreement With Queen Mary University 15
BioMoti Enters into Licensing Agreement with Queen Mary University of London 16
MultiVir Enters into Licensing Agreement with Queen Mary University of London 17
Retroscreen Virology Acquires Activiomics for USD6.7 Million 18
Queen Mary University of London, Key Competitors 20
Queen Mary University of London, Key Employees 21
Queen Mary University of London, Subsidiaries 22

★海外企業調査レポート[Queen Mary University of London-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Maruzen Petrochemical Co Ltd:企業の戦略的SWOT分析
    Maruzen Petrochemical Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Targa Resources Partners LP (NGLS PR A):企業の財務・戦略的SWOT分析
    Targa Resources Partners LP (NGLS PR A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Copan Italia SpA:医療機器:M&Aディール及び事業提携情報
    Summary Copan Italia SpA (Copan Italia) is a medical equipment provider that offers lab consumables and diagnostic products. The company’s products include clinical products, lab automation products, and genetics, forensics, and lab consumable products, among others. Its lab automation products allo …
  • NOV Inc (NOV):企業の財務・戦略的SWOT分析
    NOV Inc (NOV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Velan Inc (VLN):企業の財務・戦略的SWOT分析
    Velan Inc (VLN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Cholamandalam Investment and Finance Company Ltd (CHOLAFIN):企業の財務・戦略的SWOT分析
    Cholamandalam Investment and Finance Company Ltd (CHOLAFIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the comp …
  • Swiss Post Ltd:企業の戦略的SWOT分析
    Swiss Post Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Abeona Therapeutics Inc (ABEO)-医療機器分野:企業M&A・提携分析
    Summary Abeona Therapeutics Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is a biopharmaceutical company focusing on the development and delivery of gene therapy and plasma-based products for severe and life-threatening rare diseases. The company’s lead programs include ABO-101 and ABO …
  • Celyad SA (CYAD):企業の財務・戦略的SWOT分析
    Summary Celyad SA (Celyad), formerly Cardio3 BioSciences, is a clinical-stage biopharmaceutical company that offers discovery and development of engineered cell therapies. The company offers C-Cure, a cell-based reparative therapy to treat heart failure. It offers C-Cathez, an intraventricular injec …
  • G4S Plc (GFS):企業の財務・戦略的SWOT分析
    G4S Plc (GFS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • NanoRepro AG (NN6):医療機器:M&Aディール及び事業提携情報
    Summary NanoRepro AG (NanoRepro) is a manufacturer of fast-diagnostics and nutritional food supplements for home and clinical use. The company offers wide range of rapid diagnostic tests products in the areas of family planning, disease detection (preventive healthcare), food intolerances, allergies …
  • QIAGEN N.V.:企業の戦略・SWOT・財務情報
    QIAGEN N.V. - Strategy, SWOT and Corporate Finance Report Summary QIAGEN N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Edison International (EIX):企業の財務・戦略的SWOT分析
    Edison International (EIX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • SciBase AB (SCIB)-医療機器分野:企業M&A・提携分析
    Summary SciBase AB (SciBase) is a medical technology company that offers non-invasive detection and monitoring of skin tissue alterations. The company has developed point of care device for the accurate detection of malignant melanoma. It offers products which include electrical impedance spectrosco …
  • SeraCare Life Sciences, Inc.-医療機器分野:企業M&A・提携分析
    Summary SeraCare Life Sciences, Inc. (SeraCare) carries out the discovery, development, manufacture and supply of disease-state specimens and tissues for research and development, processed biological materials, immunoassay reagents and quality control products and technologies. Its major products i …
  • MTY Food Group Inc.:戦略・SWOT・企業財務分析
    MTY Food Group Inc. - Strategy, SWOT and Corporate Finance Report Summary MTY Food Group Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Biomay AG-製薬・医療分野:企業M&A・提携分析
    Summary Biomay AG (Biomay) discovers and develops disease modifying allergy therapeutics. The company develops peptide carrier fusion vaccines for allergy immunotherapy. Its pipeline product portfolio comprises investigation candidates targeted against IgE mediated diseases, grass pollen allergy, ho …
  • Innovative Solutions and Support, Inc.:企業の戦略・SWOT・財務分析
    Innovative Solutions and Support, Inc. - Strategy, SWOT and Corporate Finance Report Summary Innovative Solutions and Support, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Acciona SA (ANA):電力:M&Aディール及び事業提携情報
    Summary Acciona SA (Acciona) is a provider of sustainable solutions for infrastructure and renewable energy projects. The company develops and manages infrastructure, renewable energy, water, and other facilities. Its operations cover the whole value chain, from design and construction to operation …
  • Fnm Spa
    Fnm Spa - Strategy, SWOT and Corporate Finance Report Summary Fnm Spa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆